Tag: Vegf inhibitor

In July 2014, the U.S. Food and Drug Administration (FDA) first approved EYLEA (aflibercept) for the treatment of diabetic macular edema (DME). This pivotal approval, based on robust clinical trial data, established EYLEA as a standard of care for a significant complication of diabetic eye disease.

Although considered a low risk, clinical trial data showed that patients receiving Vabysmo have experienced serious, sometimes fatal, arterial thromboembolic events (ATEs), such as heart attacks or strokes. This raises the important question: Can vabysmo cause heart problems? The potential for cardiovascular side effects is a critical consideration for patients and healthcare providers.

Eylea, a widely prescribed medication for serious retinal conditions, does not have a traditional generic version because it is a biologic drug, not a chemically synthesized one. Its generic, or official reference, name is aflibercept, and with the recent patent expirations, several biosimilar versions are now available, offering new, potentially more affordable, treatment options.

The list price for Lucentis (ranibizumab), often misspelled as Accentrix, can be approximately $1,575 to $2,000 per injection [1.2.2, 1.2.4]. What is the cost of Accentrix injection and what factors determine the final price for patients needing this critical eye treatment?

First approved in 2004, Avastin was the first therapy designed to inhibit angiogenesis, or the formation of new blood vessels, that became available in the United States [1.4.2, 1.6.1]. So, **what is AVA medication**? In oncology, it often refers to Avastin (bevacizumab), a targeted therapy used to treat many types of cancer [1.3.2].